AccessibilityHelp
Helus Pharma logo

Helus Pharma(NASDAQ) HELP

Market Cap$744.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-61%
5 Year-86%
1 Year+70%
1 Month-22%
$10.15
-3.33%
-0.35Today
After hours$10.28+$0.13 (+1.28%)
Helus Pharma last closing stock price
MetricPriceDate
Last closeUSD 10.192026-10-23
Helus Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.41%USD 10.552026-10-16
1 month-21.74%USD 13.022026-09-23
3 month+33.73%USD 7.622026-07-24
Year to date+24.57%USD 8.182025-12-31
1 year+69.83%USD 6.002025-10-23
3 year-39.12%USD 16.742023-10-24
5 year-86.32%USD 74.482021-10-22
Since inception-61.35%USD 26.362020-11-11

Helus Pharma Financials at a Glance

Market Cap

$744.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$183.27M

EPS (TTM)

-$4.25

P/E Ratio

-2.40

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$10.15

Volume

1,894,832.76

Open

$10.50

Previous Close

$10.19

Daily Range

$9.87 - $10.75

52-Week Range

$3.76 - $15.15

Estimated Earnings Date

Nov 12, 2026

HELP News

Hands holding some pills from a bottle

5 Best Psychedelic Stocks for 2026 and How to Invest

Keith SpeightsSep 10, 2026
scientist talks with coworkers at table

These 4 Psychedelic Biotech Stocks Are Leading the Pack

Alex CarchidiOct 26, 2021
neurologist shows patient a brain scan image

Buying Cybin Stock Right Now Could Be a Brilliant Move

Alex CarchidiSep 2, 2021
Woman with light bulbs

Missed the Initial Cannabis Boom? Check Out Hot Psychedelic Stock Cybin

Keith SpeightsJul 1, 2021
three doctors and three nurses discuss a readout at a table

3 Reasons to Buy Cybin Stock, and 1 Reason to Sell

Alex CarchidiJun 26, 2021
standing pair of investors consider tablet and computer

Could Cybin Be a Millionaire-Maker Stock?

Alex CarchidiJun 17, 2021
Hand drawing psilocybin chemical structure

Forget Sundial Growers: Put This Psychedelic Stock on Your Radar

Keith SpeightsApr 29, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Helus Pharma

Helus Pharma Inc. is a clinical-stage pharmaceutical company focused on developing proprietary serotonergic agonists aimed at treating mental health conditions. The company is advancing its pipeline with HLP003, currently in Phase 3 for major depressive disorder, and HLP004, in Phase 2 for generalized anxiety disorder.

Products and Services
  • HLP003: Phase 3 development for major depressive disorder
  • HLP004: Phase 2 development for generalized anxiety disorder
  • Research and development of serotonergic agonists for mental health
Growth Outlook
  • Strong pipeline with two drugs in advanced clinical stages
  • Increasing demand for mental health treatments globally
  • Potential for significant market share in the mental health sector
Financial Highlights
  • Cash and cash equivalents of $166.17 million as of June 30, 2026
  • Operating expenses of $47.84 million in Q1 2026
  • Net income of -$46.60 million for Q1 2026, reflecting ongoing investment in R&D
Helus Pharma Inc. is positioned in a growing market with a focus on innovative treatments for mental health disorders. The company's commitment to research and development is evident in its substantial operating expenses, which are aimed at advancing its drug pipeline. With a strong cash position, Helus Pharma is well-equipped to navigate the challenges of clinical trials and regulatory approvals. The increasing global demand for effective mental health treatments presents a significant opportunity for the company to capture market share and drive future growth.
AI Generated • Oct 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

100

CEO

Eric So

Website

www.cybin.com

Headquarters

Toronto, ON M5X 1C9, CA

HELP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-74.47%

Return on Capital

-61.00%

Return on Assets

-67.58%

Earnings Yield

-41.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$744.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

73.06M

Volume

1.89M

Avg. Volume

1.70M

Financials (TTM)

Gross Profit

-$30.21K

Operating Income

-$177.17M

EBITDA

-$177.05M

Operating Cash Flow

-$152.97M

Capital Expenditure

-$1.62M

Free Cash Flow

-$154.59M

Cash & ST Invst.

$166.17M

Total Debt

$0.00

Helus Pharma Performance Analysis

Helus Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Helus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Q12026-06-30N/A
Helus Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -7.36-40.0%
20242024-03-31USD -2.89-60.7%
20252025-03-31USD -4.0239.0%
20262026-03-31USD -4.255.7%
Helus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-76.4%
Q32025-12-319.3%
Q42026-03-3147.7%
Q12026-06-303.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$30.21K

N/A

Gross Margin

0.00%

N/A

Market Cap

$744.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.44M

N/A

Employees

100

N/A

Net Income

-$46.60M

-89.4%

EBITDA

-$47.81M

-94.4%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$166.17M

+90.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$5.03M

+67.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-67.58%

N/A

Return on Invested Capital

-70.77%

N/A

Free Cash Flow

-$36.44M

-66.7%

Operating Cash Flow

-$36.13M

-66.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,623.68-0.01%
^DJIDJI
$52,215.16-0.01%
^IXICNASDAQ
$25,955.34-0.00%
BTCBitcoin
$80,332.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About HELP

What is the current price of Helus Pharma?

Helus Pharma is trading at $10.19 per share.

What is the 52-week range for Helus Pharma?

Over the past 52 weeks, Helus Pharma has traded between $3.76 and $15.15.

How much debt does Helus Pharma have?

As of the most recent reporting period, Helus Pharma reported total debt of $0.00.

How much cash does Helus Pharma have on hand?

Helus Pharma reported $166.37M in cash and cash equivalents in its most recent financial results.

What is Helus Pharma’s dividend yield?

Helus Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services